^
Association details:
| Biomarker: | MET amplification + MET Exon 14 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
Published date:
04/04/2022
Excerpt:
...we firstly described a 61-year-old woman with lung adenocarcinoma who harbored a novel MET exon 14 skipping (c.3004_3028+3del) concurrent MET amplification (copy number: 3.91) and benefited from Savolitinib treatment….After 2 months of Savolitinib treatment, the clinical evaluation was a partial response (PR).
DOI:
https://doi.org/10.3389/fonc.2022.863560
